Investigating how CDCP1 contributes to autoimmune uveitis
Official title: Role of CDCP1 in the pathogenesis of autoimmune uveitis
Funded at Cleveland Clinic Lerner Com-Cwru · NIH-10873898 · Data updated 2026-11-12
This study is looking at a protein called CDCP1 to see how it affects the movement of harmful T cells in the eye, which could help us find new ways to treat autoimmune uveitis and protect your vision.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $504,011 |
| NIH project number | 5R01EY034077-02 |
| Project ID | NIH-10873898 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with autoimmune uveitis or those at risk of developing this condition.
✕Less likely to help
Patients with other forms of uveitis not related to autoimmune processes may not benefit from this research.
What this research studies
This research focuses on understanding the role of CDCP1, a protein that may influence the development of autoimmune uveitis, a condition that can lead to blindness. The study involves examining how CDCP1 affects the infiltration of harmful T cells through the blood-retina barrier, which is crucial for maintaining eye health. By using specialized techniques and reagents, researchers aim to uncover the mechanisms by which CDCP1 interacts with T cells and impacts retinal cells, potentially leading to new treatment strategies for patients suffering from this condition.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic approaches for treating autoimmune uveitis, potentially reducing the risk of blindness.
How similar studies have gone: Previous research has shown promising results in targeting similar pathways in autoimmune diseases, suggesting potential for success in this approach.
Where this research is happening
-
Cleveland Clinic Lerner Com-Cwru
Cleveland, United States Active
Researchers
- Principal investigator: Lin, Feng C — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Lin, Feng C
Related research
Other NIH-funded projects on the same topics.
-
Adalimumab Dose Adjustment for Pediatric Uveitis in JIA
A pediatric study will test whether lowering how often kids with juvenile idiopathic arthritis–related uveitis take adalimumab can keep inflammation controlled while reducing side effects and cost.
-
Changing adalimumab dosing for children with juvenile arthritis–related eye inflammation
This project tries to see if giving lower or less frequent doses of adalimumab can keep eye inflammation under control in children with juvenile idiopathic arthritis.
-
Systemic and topical antiviral treatment for CMV anterior uveitis (STACCATO)
A new NIH-supported effort will test how well oral and eye-applied antiviral medicines control CMV-related anterior uveitis in affected patients.
-
Systemic and topical antiviral treatment for CMV anterior uveitis in patients
A patient-friendly look at using antiviral medicines to treat CMV-related eye inflammation and protect vision.
-
Systemic and topical antiviral treatment for CMV anterior uveitis
This project tests how oral and eye-drop antiviral medicines can help prevent vision loss from CMV-related eye inflammation in people with anterior uveitis.
-
Systemic and topical antiviral control of CMV anterior uveitis: TreatmentOutcomes
A patient-focused look at how CMV eye inflammation in adults could be treated with pills, eye drops, or other strategies to prevent vision loss.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.